Congress enlists GAO in drug shortages probe

Another U.S. congressman has boarded the drug-supply bandwagon. Sen. Richard Blumenthal of Connecticut has asked the Government Accountability Office to investigate recent and growing shortages.

His request follows last month's legislation proposal by Sens. Amy Klobuchar of Minnesota and Bob Casey of Pennsylvania that would require drugmakers to give the FDA early notice of supply interruptions.

Blumenthal sees a need for stronger action, according to the Hartford Courant. He wants GAO to determine what causes the shortages and how they affect patient care. His office, meanwhile, will look into pharma's knowledge of impending shortages and its responsibility to maintain adequate supplies. He plans also to investigate the timing of pharma shortage alerts to hospitals.

- read the story
- here's more on the Klobuchar/Casey effort

Suggested Articles

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Continuing its expansion efforts, Japan’s Fujifilm will make a major investment in its U.S. gene therapy operation in Texas.